258 results about "Α galactosidases" patented technology

The invention relates to the technical field of spermidine application, in particular to application of spermidine in preparation of medicine for preventing and treating doxorubicin-induced cardiotoxicity and myocardial aging. Cell proliferation experiments and mouse survival rate experiments show that spermidine can reduce death of myocardial cells and mice caused by adriamycin; a q-PCR experiment shows that spermidine can improve abnormal expression conditions of P53, P21, P16, BAX, TNF-alpha, IFN alpha, IL-10 and IL-18 in myocardial cells caused by adriamycin; a beta-galactosidase staining experiment shows that the spermidine can reduce the condition that the expression of a marker beta-galactosidase for myocardial cell senescence induced by adriamycin is increased; a Western Blot experiment shows that the spermidine can improve the condition that the P53 protein is abnormally increased due to the adriamycin; an Elisa experiment shows that spermidine can improve the condition that myocardial injury markers cTn-I and AST and inflammatory factors IL-1beta are abnormally increased due to adriamycin, and the myocardial injury markers cTn-I and AST and inflammatory factors IL-1beta are abnormally increased due to adriamycin. Therefore, spermidine can improve cardiotoxicity and myocardial aging induced by adriamycin.

The present invention belongs to the field of cosmetics detection, and discloses a method for evaluating the sun protection function of cosmetics and cosmetic raw materials and its application. This evaluation method uses a non-contact drug delivery device to test the sun protection effect of the test samples, and the test samples are finished cosmetics or diluted cosmetic raw materials; the tests include evaluating the in vitro sun protection efficacy by skin cells, evaluating the in vivo sun protection efficacy by the zebrafish embryo model, and result evaluation. This method evaluates the anti-aging effect of sun protection through the expression of β-galactosidase and / or the secretion of collagen in human dermal fibroblasts, and evaluates the sunburn prevention effect through the survival rate of human keratinocytes, DNA damage, or the secretion of inflammatory factors and the lethal / teratogenic conditions of zebrafish embryos, realizing multi-level and all-round evaluation of the sun protection efficacy. The method provided by the present invention is applicable to the evaluation of the sun protection function of various sun protection products, has accuracy and practicability, and provides an important technical basis for the research and development, quality control, and performance optimization of sun protection cosmetics.

The invention provides application of scEMC10 in treatment and diagnosis of cerebral vascular endothelial cell senescence, and relates to the technical field of biomedicine. The research of the inventor finds that brain microvascular endothelial cell senescence is caused by the lack of scEMC10; after the brain microvascular endothelial cells are treated by scEMC10, beta-galactosidase, SASP and classic senescence markers related to senescence can be down-regulated; after scEmc10 is supplemented to old mice and Alzheimer's disease 5XFAD model mice, the motion coordination ability and the spatial cognitive ability of the mice can be obviously improved, the relative content of a marker phosphorylated alpha-synuclein of the Parkinson's disease of the old mice can be obviously reduced, and the content of tyrosine hydroxylase phosphorylated active forms can be increased. Therefore, the scEMC10 can be used for treating brain microvascular endothelial cell senescence, improving Alzheimer's disease and Parkinson's disease and detecting brain microvascular endothelial cell senescence as a marker.

The invention discloses a nerve cell senescence resisting medicine containing p-hydroxybenzaldehyde and application thereof.The p-hydroxybenzaldehyde is adopted as the only active substance, and the p-hydroxybenzaldehyde can reduce accumulation of DNA damage in cells, reduce activity of beta-galactosidase in the cells and slow down reduction of cell metabolic capacity, so that the nerve cell senescence resisting medicine is obtained. Therefore, the senescence of nerve cells is effectively slowed down, the cognitive function is improved, and a potential treatment effect is achieved in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

The invention provides an anti-aging composition and application thereof, the composition at least contains pyrroloquinoline quinone disodium salt, ergothioneine and 5-aminolevulinic acid or salt thereof in physiologically acceptable media, the composition contains PQQ, ergothioneine and 5-aminolevulinic acid (5-ALA) or salt thereof, the three components are compounded to achieve a synergistic effect, and the anti-aging effect is achieved. The dyeing intensity of beta-galactosidase is reduced, and the anti-aging effect is achieved.

The invention belongs to the technical field of analysis and detection, and particularly relates to a beta-galactosidase response type hemicyanine near-infrared fluorescent probe, a preparation method thereof and application of the beta-galactosidase response type hemicyanine near-infrared fluorescent probe as a tumor organ imaging probe. The near-infrared fluorescent probe provided by the invention takes a water-soluble hemicyanine skeleton as a fluorophore, so that the biocompatibility of the near-infrared fluorescent probe is improved; based on the principle that beta-galactose can be selectively cut by beta-galactosidase, a galactose structure with a self-leaving group is used as a response group, selective quick response to the beta-galactosidase is achieved, and high sensitivity to the beta-galactosidase is shown. The near-infrared fluorescent probe provided by the invention can emit near-infrared fluorescence with long wavelength, has lower background fluorescence and good penetration depth, and can be directly used for detecting organoids containing the matrigel without eliminating the matrigel, so that the organoids are prevented from being damaged or additional experimental variables are prevented from being introduced in the process of eliminating the matrigel.

The invention discloses a preparation method of mannan oligosaccharide, and relates to the technical field of organic agricultural fertilizers. According to the method, high-purity and high-efficiency mannan oligosaccharide is prepared by using an advanced process, and the method comprises the following specific steps: pretreatment of raw materials: mixing konjaku flour or guar gum with water to obtain a colloidal solution; adding beta-mannase and alpha-galactosidase into the colloidal solution, and carrying out enzymolysis under the assistance of a pulsed electric field; performing secondary separation on the enzymatic hydrolysate through an ultrafiltration membrane and a nanofiltration membrane, and collecting trapped fluid. A calcium ion solution is added into the trapped fluid for a complex reaction, then spray drying is conducted, and mannan oligosaccharide powder is obtained. According to the method, mannan oligosaccharide with concentrated purity and polymerization degree is prepared through ultrahigh pressure homogenization, pulsed electric field assisted enzymolysis and membrane separation technologies, the method has the advantages of high efficiency and environmental protection, and the preparation efficiency and the product quality are remarkably improved. The prepared mannan oligosaccharide can be applied to organic agricultural fertilizers, and can be compounded with humic acid and other substances to improve the biological activity and soil fertility of the fertilizers.

The invention discloses efficient expression of an aspergillus oryzae beta-galactosidase mutant and application of the aspergillus oryzae beta-galactosidase mutant in dairy products. The invention belongs to the technical field of enzyme engineering and the technical field of dairy product processing, and particularly relates to efficient expression of an aspergillus oryzae beta-galactosidase mutant and application of the aspergillus oryzae beta-galactosidase mutant in dairy products. The mutant protein disclosed by the invention can be as follows: A1) a protein with an amino acid sequence of SEQ ID No.2; a2) a fusion protein which is obtained by connecting a label to the N end and / or the C end of A1) and has the same function. The mutant protein is subjected to high-density fermentation in a 5L fermentation tank, the enzyme activity of fermentation liquor can reach 4628U / mL, and the recovery rate of mutant enzyme is increased by 1.7 times. Compared with a wild type, the mutant has the advantages that the optimum pH is increased from 4.5 to 5.5, the optimum temperature is reduced from 60 DEG C to 50 DEG C, the lactose hydrolysis efficiency is improved by 11%, and the mutant is more suitable for a production process of low / zero lactose dairy products.

The invention relates to the technical field of prebiotics preparation, and discloses a preparation method of prebiotics applied to reproduced areca catechu, and the preparation method comprises the following steps: carrying out enzyme catalysis reaction on sucrose by adopting fructosyl transferase to prepare fructo-oligosaccharide; according to the method, beta-galactosidase is adopted to carry out enzyme catalysis reaction on lactose, so that galactooligosaccharide is prepared; respectively carrying out decoloration, ion exchange, nanofiltration concentration and spray drying on the candy oligosaccharide and the galactooligosaccharide to obtain powder; the method comprises the following steps: mixing fructo-oligosaccharide powder and galactooligosaccharide powder according to a ratio, and uniformly distributing the mixture in a reproduced areca-nut matrix by adopting a spray-drying blending or low-temperature vacuum mixing mode to form a functional reproduced areca-nut product; according to the invention, low-temperature drying is carried out on the product after blending or vacuum mixing, so that the prebiotic areca nuts are released along with saliva in the chewing process, and are selectively utilized by bifidobacteria and lactic acid bacteria after entering the stomach and intestine, thereby achieving the purposes of regulating intestinal flora and improving the health-care function.

The invention relates to a serum-free culture medium for culturing mesenchymal stem cells as well as a preparation method and application of the serum-free culture medium. Wherein the serum-free culture medium comprises a complete culture medium and praeruptorin E, and the content of the praeruptorin E in the serum-free culture medium is 0.25-3 [mu] M. The inventor finds that a serum-free culture medium containing a certain concentration of praeruptorin E can effectively improve the decline of replicative activity of mesenchymal stem cells in in-vitro passage. Specifically, the serum-free culture medium containing the praeruptorin E with a certain concentration can reduce the expression level of a marker beta-galactosidase with reduced replicative activity in the mesenchymal stem cells with reduced replicative activity after multiple in-vitro passage, reduce the expression of a gene CDKN1A with reduced replicative activity, and increase the multiplication capacity of the mesenchymal stem cells; the mitochondrial damage is reduced.

The invention discloses a pharmaceutical composition for delaying oocyte senescence and application thereof, and relates to the technical field of biological medicine, and the pharmaceutical composition comprises alpha-ketoglutaric acid, a bicarbonate buffer solution, an energy metabolism substrate, polyvinyl alcohol, hormone, a growth factor and insulin-transferrin-selenium. The pharmaceutical composition for delaying oocyte aging disclosed by the invention is beneficial to improving the maturation rate of oocytes, reducing the cytoplasm fragmentation rate and the cleavage fragmentation rate, and improving the cleavage rate and the blastocyst rate; according to the invention, the content of beta-galactosidase is reduced, the function of mitochondria in the aging process after ovulation of the mature oocyte is improved, the membrane potential of the mitochondria in the aging process after ovulation of the mature oocyte is stabilized, the activity of the mitochondria is improved, and the normalization of RNA methylation modification in the aging process after ovulation of the mature oocyte is promoted.

The invention discloses a beta-galactosidase mutant derived from bifidobacterium bifidum and application thereof, and belongs to the technical field of enzyme engineering. The invention aims to improve the GOS synthesis yield and shorten the treatment time. The invention provides a beta-galactosidase mutant derived from bifidobacterium, and the mutant is obtained by mutating a 531 site, a 682 site, a 747 site or a 710 site by taking SEQ ID No.1 as a starting sequence. The glucoside conversion rate of the mutant W710F after reacting in a 350g / L lactose system for 5 hours reaches 45.90%, and is increased by 53.87% compared with that of a wild type. The beta-galactosidase mutant has the excellent properties of high catalytic efficiency and high yield of galactooligosaccharide, the cost of prebiotics is reduced, the conversion efficiency of producing galactooligosaccharide by using the beta-galactosidase mutant is improved, and the beta-galactosidase mutant has great industrial production and application potential and economic value.

The invention relates to a chemiluminescence kit for detecting pepsinogen II. The kit comprises an enzyme marker, a luminescent substrate solution and an anti-interference buffer system, the anti-interference buffer system comprises a nonionic surfactant, animal-derived IgG (immunoglobulin G), an antioxidant and catalase; the chemiluminescence kit also comprises a PG II calibration product and a PG II quality control product. The core active component of the enzyme marker is beta-galactosidase. The enzyme marker further comprises an anti-PG II monoclonal antibody marked by beta-galactosidase, bovine serum albumin, trehalose, cane sugar, MgCl2. 6H2O, sodium chloride, Proclin300 and a phosphate buffer solution. According to the kit, a brand-new anti-interference buffer system is introduced on the basis of a spatial proximity chemiluminescence analysis method, so that the resistance to clinically common interferents (such as hemolysis, lipemia, jaundice and heterotropism antibodies) is remarkably improved, and the detection result is more accurate and reliable.

The application discloses efficient expression of Aspergillus oryzae beta-galactoside enzyme mutant and application thereof in dairy products, and belongs to the technical fields of enzyme engineering and dairy product processing, and particularly relates to efficient expression of Aspergillus oryzae beta-galactoside enzyme mutant and application thereof in dairy products.The mutant protein can be as follows: A1) a protein with an amino acid sequence of SEQ ID No.2; A2) a fusion protein with the same function obtained by connecting a label to the N terminal and / or C terminal of A1).The mutant protein is subjected to high-density fermentation in a 5L fermentation tank, and the enzyme activity of the fermentation liquor can reach 4628U / mL, and the recovery rate of the mutant enzyme is increased by 1.7 times.Compared with the wild type, the optimal pH of the mutant is increased from 4.5 to 5.5, the optimal temperature is decreased from 60 DEG C to 50 DEG C, the lactose hydrolysis efficiency is increased by 11%, and the mutant is more suitable for the production process of low / zero lactose dairy products.

The invention provides a high-activity beta-galactosidase mutant as well as a preparation method and application thereof. In the invention, a series of beta-galactosidase mutants are successfully obtained by analyzing a three-dimensional space structure of a compound of wild type beta-galactosidase, a substrate and metal ions and carrying out site-specific mutagenesis, combined mutagenesis and combined random mutagenesis on amino acid sites related to beta-galactosidase activity and substrate combination; and the enzymatic activity is remarkably improved.

The invention discloses an application of bulbus lilii glycoside B. The application is that bulbus lilii glycoside B is used as a unique active component or one of the active components to prepare a product for preventing or / and treating skin photoaging diseases. Experimental results of the invention show that lilium brownii glycoside B can significantly improve the cell viability of UVA-induced human skin fibroblasts, can reduce the number of beta-galactosidase positive cells in the UVA-induced human skin fibroblasts and reduce lipofuscin deposition, and can significantly improve the photoaging of the UVA-induced skin fibroblasts. Meanwhile, the skin photoaging grading of the back of a C57BL / 6 mouse induced by UVA can be remarkably improved. Therefore, the bulbus lilii glycoside B is expected to be used as an active ingredient for preparing medicines or cosmetics for preventing or / and treating the skin photoaging diseases, and particularly has important significance and remarkable application value for preventing or / and treating the UVA-induced skin photoaging diseases.

The invention relates to a beta-galactosidase mutant with improved thermal stability and pH stability, and belongs to the technical field of enzyme engineering. The beta-galactosidase derived from Kluyveromyces lactis is subjected to molecular modification, a potential mutation site is determined by using an alanine scanning strategy, beta-galactosidase mutants Pro433Ala and Asp441Ala of which the thermal stability and the pH stability are simultaneously improved are obtained through site-directed mutagenesis screening, the catalytic efficiency of the mutants is improved to 1.03-1.18 times compared with that of the mutants before optimization, and the beta-galactosidase mutant can be used for preparing beta-galactosidase. Wherein the maximum half-life period of the mutant Asp441Ala under the condition of 50 DEG C reaches 91.5 minutes and is increased by 213.4% compared with that of a wild type, the problems of poor catalytic thermal stability and poor pH stability of beta-galactosidase in the prior art are solved, and a brand-new tool is provided for obtaining galactooligosaccharide by using beta-galactosidase to hydrolyze lactose.

The invention discloses a fluorescent / photoacoustic dual-mode diagnosis and treatment probe for detection and photodynamic removal of senescent cells, a preparation method and application, the probe takes a sulfur-substituted hemicyanine dye as a parent structure, a novel bromo-glycoside ligand is covalently coupled, and a blue-green solid is obtained after gradient purification. The probe system shows a remarkable optical response characteristic on beta-galactosidase (beta-Gal) and ideal singlet oxygen (1O2) generation efficiency; an optical signal and a photodynamic therapy effect of the probe can be specifically activated by beta-galactosidase (beta-Gal) overexpressed in cancerous cells and senescent cells under a light excitation condition; the result is successfully verified in a palbociclib-induced senescence melanoma model. According to the probe disclosed by the invention, collaborative regulation and control of dual-mode visual monitoring and precise photodynamic therapy of beta-Gal enzyme activity are realized for the first time, a novel tool is provided for researching a molecular mechanism of cell aging and developing a diagnosis and treatment strategy of aging-related diseases, and the probe has a remarkable application value in the fields of anti-tumor treatment and degenerative diseases.

The invention belongs to the technical field of medicine research, and particularly relates to application of eicosapentaenoic acid in preparation of a medicine for preventing and treating myocardial cell death and senescence induced by adriamycin. Experiments prove that a low dose (15 [mu] M) of eicosapentaenoic acid (EPA) has no obvious toxicity to H9C2 myocardial cells, and the low dose (15 [mu] M) of EPA can improve the death phenomenon of the H9C2 myocardial cells caused by adriamycin; the EPA can be used for reducing the increase of the content of beta-galactosidase in adriamycin-induced H9C2 cells. P53 and P21 related to aging are highly expressed after being treated by 0.5 uM DOX of H9C2 myocardial cells, and EPA can obviously reduce the expression of the P53 and P21. After DOX treatment, the expression of core proteins G3BP1G3BP1 and UBAP2L of stress particles in the H9C2 myocardial cells is increased, and the phenomenon can be improved by EPA (eicosapentaenoic acid). The experiments prove that eicosapentaenoic acid can improve death and aging of adriamycin-induced H9C2 myocardial cells.

The invention belongs to the technical field of daily cosmetics, and particularly relates to a preparation method and application of a sparassis crispa extract. The sparassis crispa extract is subjected to water extraction and enzymolysis with a specific enzyme such as beta-galactosidase, so that the transfer rate of active ingredients such as polysaccharide is remarkably increased. After a specific type of macroporous resin is subsequently adopted for purification, the Gardner chromatic value of active ingredients such as polysaccharide is obviously reduced, in addition, the prepared sparassis crispa extract shows the effects of inhibiting inflammatory factor secretion, keratinocyte migration and collagen loss in a cell experiment, wound healing and repairing are facilitated, and the application prospect is wide. A new thought is provided for preparing products such as skin care and beauty makeup products with post-medical repair and barrier repair effects.

Described herein are novel engineered peptides, viral vectors, and pharmaceutical compositions thereof, and uses of the same for increasing α-GAL A expression and for the treatment of conditions associated with α-GAL A deficiency, such as Fabry disease.

The invention relates to a preparation method and application of erythritol galactoside. The method specifically comprises the following steps: constructing a reaction system which takes o-nitrobenzene-beta-D-galactopyranoside as a glycosyl donor, erythritol as a receptor and recombinant beta-galactosidase Bga7 as a catalytic enzyme, so as to prepare the erythritol-beta-galactoside. Wherein the amino acid sequence of the beta-galactosidase Bga7 is as shown in SEQ ID No.2, and the nucleotide sequence of the beta-galactosidase Bga7 is as shown in SEQ ID No.1. The invention also provides an application of the erythritol-beta-galactoside in preparation of daily chemical products or medical preparations for resisting streptococcus mutans infection. The invention provides a novel beta-galactosidase Bga7 gene of a glycosidase family 2, and a novel tool enzyme is provided for synthesis of galactoside products. The erythritol-beta-galactoside prepared by the invention has good effects of preventing streptococcus mutans infection and caries, and can be used for preparing daily chemical products or medical preparations for preventing streptococcus mutans infection.

Aspects of the disclosure relate to compositions and methods for the treatment of lysosomal storage disorders, such as GM1 gangliosidosis, Tay Sachs disease, and Sandhoff disease. In some embodiments, the compositions comprise viral vectors encoding beta-galactosidase. In some embodiments, the compositions comprise viral vectors encoding beta-hexosaminidase subunits (e.g. HEXA, HEXB, or combinations thereof).

A composition including a gene therapy delivery system and an alpha-galactosidase (GLA) polynucleotide encoding a GLA polypeptide, wherein the GLA polypeptide has at least 95% sequence identity to one of SEQ ID NOS. 1-40, 44-45, 51-52, 57, 61-173 or 212. Also provided are compositions, formulations, fusion proteins, and methods for the treatment of Fabry disease.

The present invention discloses a photosensitizer prodrug compound (structural formula (I)) that selectively clears senescent cells and is specifically activated by the aging-associated β-galactosidase, as well as its preparation method and application. Upon activation by β-galactosidase, the compound rapidly releases its active molecule, anchoring it to proteins with nucleophilic groups. This allows for precise detection and covalent anchoring of senescent cells, thereby achieving selective clearance of senescent cells, reversing senescence-related markers and gene expression, and ameliorating aging-related decline in bodily functions. #imgabs0#

The invention relates to the technical field of daily cosmetics, in particular to a peony extract with scalp anti-aging and anti-hair-loss functions and application. The peony extract disclosed by the invention is a peony flower extract, the mass fraction of peony flower peptide in the peony flower extract is greater than or equal to 10%, and the peony extract disclosed by the invention is found to have the effects of improving the activity of superoxide dismutase (SOD) on human hair papilla cells for the first time; the positive cell rate of beta-galactosidase (SA-beta-Gal) of human hair papilla cells is inhibited, and the functions of senescent cells are reduced; meanwhile, the functions of promoting hair follicles to express growth factors and promoting hair growth are achieved. The method can be applied to preparation of scalp care products, and the anti-aging or anti-hair-loss function of scalp is achieved.

This invention provides a method for screening β-galactosidase inhibitors, belonging to the field of pharmaceutical technology. The first step of this method uses fluorescence sensing technology to rapidly identify natural products with β-Gal inhibitory activity. The principle is based on the fluorescence quenching property of p-nitrophenol (PNP) on sulfur quantum dots (SQDs); β-Gal catalyzes the hydrolysis of p-nitrophenyl-β-D-galactopyranoside (PNPG) to generate the specific product PNP; in the presence of β-Gal, PNPG can be enzymatically catalyzed to generate PNP, quenching the fluorescence of SQDs; when screened for β-Gal inhibitory activity, the fluorescence of SQDs can be restored. The second step uses affinity chromatography to capture components in samples with β-Gal inhibitory activity. This method involves immobilizing β-Gal on a support material, eluting with a solvent to obtain components that can bind to β-Gal, and then using liquid chromatography-mass spectrometry (LC-MS) to identify the components. This method can rapidly and accurately screen β-Gal inhibitors from natural products.

The invention provides a near-infrared beta-galactosidase fluorescent probe as well as preparation and application thereof, and relates to the technical field of fluorescent probes, according to the near-infrared beta-galactosidase fluorescent probe, when beta-galactosidase exists, a D-galactosyl group can be split, meanwhile, self-elimination of p-hydroxybenzyl is removed, a fluorescent signal unit is released, and the beta-galactosidase can be detected by the near-infrared beta-galactosidase fluorescent probe. The fluorescence signal is obviously enhanced. Excitation and emission spectra of the near-infrared beta-galactosidase fluorescent probe are both in a near-infrared region, the fluorescence intensity at 760 nm is rapidly increased, the fluorescence intensity rapidly reaches a stable state after 30 min, and compared with a visible light probe, the near-infrared beta-galactosidase fluorescent probe has deeper tissue penetrating capacity, background interference can be effectively avoided, and the resolution ratio is improved; the compound can be applied to beta-galactosidase detection imaging and preparation of beta-galactosidase detection imaging reagents, especially breast cancer detection reagents.

The application discloses a high-temperature-resistant alkaline alpha-galactosidase mutant and a preparation method thereof. The mutant is obtained by performing site-directed mutation on alpha-galactosidase derived from Anoxybacillus vitaminiphilus, and at least one amino acid in three positions of 444th, 457th and 509th in the amino acid sequence shown in SEQ ID No. 1 is replaced. The asparagine Asn in the 444th position is mutated into phenylalanine Phe, the aspartic acid Asp in the 457th position is mutated into methionine Met, and the arginine Arg in the 509th position is mutated into tryptophan Trp. The alpha-galactosidase mutant has good thermal stability and alkali stability by performing site-directed mutation on alpha-galactosidase derived from Anoxybacillus vitaminiphilus (Anoxybacillus vitaminiphilus WMF1).

Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-galactosidase A, wherein the patient has a splice site mutation in intron 4 of the nucleic acid sequence encoding α-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.